Active Surveillance for Adverse Events Following Immunization With the Trivalent Influenza Vaccine (2018 Southern Hemisphere Season) Produced at Butantan Institute
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 403
- 试验地点
- 2
- 主要终点
- number of participants with adverse events following immunization (AEFI), 42 days post-vaccination.
研究概览
简要总结
Rationale and Background: Since 2013, Butantan Institute has been performing passive pharmacovigilance activities related to its triavalent, fragmented and inactivated vaccine (IB TIV).
Objetive: To conduct an active surveillance study focusing on the elderly and health care professionals as part of Butantan pharmacovigilance plan, while passive surveillance activities will continue. The pharmacovigilance plan, via active surveillance, is being implemented in response to WHO requirements for pre-qualification of IB TIV.
详细描述
Study Design: This is a prospective cohort study. Population: Target groups for vaccination defined by The National Immunization Program of Brazil: healthcare workers and elderly (people over 60 years old). Study Size: A total of 400 individuals (150 health care workers and 250 elderly), presenting for immunization with IB TIV, and who agree to participate after providing Informed Consent.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 130 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Health Care Professional; or
- •Elderly (age 60 or more); and
- •To have indication to be vaccinated against influenza, according the the Brazilian National Immunazition Programme; and
- •To be available to participate in the study throughout its duration (6 weeks after any vaccine dose administered); and
- •To demonstrates interest to participate in the study as registered in the informed consent form (ICF).
排除标准
- •Known systemic hypersensitivity to eggs or to any component of the vaccine;
- •Suspected or confirmed fever in the 3 days prior to vaccination or axillary temperature greater than 37.8 ° C on the day of vaccination;
- •History of severe adverse reaction after previous administration of an Influenza vaccine within 6 weeks following vaccination;
- •History of Guillain-Barre Syndrome or other demyelinating disease;
- •Behavioral, cognitive or psychiatric disease that in the opinion of the principal investigator or his representative physician, affects the participant ability to understand and cooperate with all study protocol requirements;
- •Any other condition in the opinion of the investigator that justifies exclusion from participation.
结局指标
主要结局
number of participants with adverse events following immunization (AEFI), 42 days post-vaccination.
时间窗: 42 days post-vaccination
to estimate the incidence of AEFI associated with administration of the trivalent, fragmented, inactivated influenza vaccine (2018 Southern Hemisphere Season) produced at Butantan Institute within 42 days post-vaccination.
次要结局
- number of solicited AEFI, 14 days post-vaccination.(14 days post-vaccination)
- number of unsolicited AEFI, 14 days post-vaccination.(14 days post-vaccination)
- number of unsolicited AEFI, 42 days post-vaccination.(42 days post-vaccination)